A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia

Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(Augusta University Health), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Nitin Jain(Parul University), Marina Konopleva(Albert Einstein College of Medicine), Varsha Gandhi(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), William Plunkett(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Lianchun Xiao(The University of Texas MD Anderson Cancer Center), Mark Brandt(The University of Texas MD Anderson Cancer Center), Zeev Estrov(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Susan O’Brien(University of California, Irvine), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center)
Cancer
July 14, 2017
Cited by 48


Related Papers